echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: Does the interval between diagnosis and the start of treatment affect the prognosis of newly diagnosed AML patients?

    Blood: Does the interval between diagnosis and the start of treatment affect the prognosis of newly diagnosed AML patients?

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Since the prognosis of acute leukemia without treatment is poor, it is recommended that patients with newly diagnosed acute myeloid leukemia (AML) begin treatment immediatelyIn a new article published in the journal Blood, researchers looked at the relationship between time and prognosis from diagnosis to the start of treatment (TDT) using a wealth of real data from the SAL-AML registry in GermanyAll registered non-APL patients (2263) received intensive induction therapy for a minimum follow-up period of 12 monthsIn the single-variable analysis, the researchers analyzed the effects of TDT on mitigation, early death, and total survival (OS) for each delayed day of treatment, divided into 0-5, 6-10, 11-15 and 15-day groups of TDT treatment, and adjusted the effects of known prognosis variables on resultsThe median TDT is 3 days (IQR 2-7)The unadjusted two-year overall survival rates (OS) for the 0-5, 6-10, 11-15 and 15-day groups were 51%, 48%, 44% and 50% respectively (p-0.211)The risk ratio (HR) of TDT as a continuous variable is 1.00 (p-0.617) in the Cox regression analysis of the multi-variable Cox regression that considers the explicit prognosis variableWhen the layered analysis was performed based on age (s.60 vs60 years old) and the initial WBC count (high vs low), there was no significant difference in OS between TDT groupsIn summary, this study shows that TDT has nothing to do with the patient's survival prognosisAs AML strengthens the stratification of first-line treatment, TDT data suggest that waiting for laboratory testresults such as genetics to assign patients with stable conditions to the best treatment options may be a viable approach
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.